Literature DB >> 11483764

Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis.

A Henke1, R Zell, G Ehrlich, A Stelzner.   

Abstract

Clinical and laboratory investigations have demonstrated the involvement of viruses and bacteria as potential causative agents in cardiovascular disease and have specifically found coxsackievirus B3 (CVB3) to be a leading cause. Experimental data indicate that cytokines are involved in controlling CVB3 replication. Therefore, recombinant CVB3 (CVB3rec) variants expressing the T-helper-1 (T(H)1)-specific gamma interferon (IFN-gamma) or the T(H)2-specific interleukin-10 (IL-10) as well as the control virus CVB3(muIL-10), which produce only biologically inactive IL-10, were established. Coding regions of murine cytokines were cloned into the 5' end of the CVB3 wild type (CVB3wt) open reading frame and were supplied with an artificial viral 3Cpro-specific Q-G cleavage site. Correct processing releases active cytokines, and the concentration of IFN-gamma and IL-10 was analyzed by enzyme-linked immunosorbent assay and bioassays. In mice, CVB3wt was detectable in pancreas and heart tissue, causing massive destruction of the exocrine pancreas as well as myocardial inflammation and heart cell lysis. Most of the CVB3wt-infected mice revealed virus-associated symptoms, and some died within 28 days postinfection. In contrast, CVB3rec variants were present only in the pancreas of infected mice, causing local inflammation with subsequent healing. Four weeks after the first infection, surviving mice were challenged with the lethal CVB3H3 variant, causing casualties in the CVB3wt- and CVB3(muIL-10)-infected groups, whereas almost none of the CVB3(IFN-gamma)- and CVB3(IL-10)-infected mice died and no pathological disorders were detectable. This study demonstrates that expression of immunoregulatory cytokines during CVB3 replication simultaneously protects mice against a lethal disease and prevents virus-caused tissue destruction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483764      PMCID: PMC115063          DOI: 10.1128/jvi.75.17.8187-8194.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Coxsackievirus B3-induced myocarditis in MHC class II-deficient mice.

Authors:  C Leipner; M Borchers; I Merkle; A Stelzner
Journal:  J Hum Virol       Date:  1999 Mar-Apr

2.  Enteroviral capsid protein VP1 is present in myocardial tissues from some patients with myocarditis or dilated cardiomyopathy.

Authors:  Y Li; T Bourlet; L Andreoletti; J F Mosnier; T Peng; Y Yang; L C Archard; B Pozzetto; H Zhang
Journal:  Circulation       Date:  2000-01-25       Impact factor: 29.690

3.  Expression of an antigenic adenovirus epitope in a group B coxsackievirus.

Authors:  K Höfling; S Tracy; N Chapman; K S Kim; J Smith Leser
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Coxsackievirus B3-induced chronic myocarditis in outbred NMRI mice.

Authors:  I Merkle; M Tonew; B Glück; M Schmidtke; R Egerer; A Stelzner
Journal:  J Hum Virol       Date:  1999 Nov-Dec

5.  Expression of cytokine mRNAs in murine hearts with acute myocarditis caused by coxsackievirus b3.

Authors:  Y Seko; N Takahashi; H Yagita; K Okumura; Y Yazaki
Journal:  J Pathol       Date:  1997-09       Impact factor: 7.996

6.  Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization.

Authors:  A Henke; E Wagner; J L Whitton; R Zell; A Stelzner
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

7.  Treatment of experimental viral myocarditis with interleukin-10.

Authors:  R Nishio; A Matsumori; T Shioi; H Ishida; S Sasayama
Journal:  Circulation       Date:  1999-09-07       Impact factor: 29.690

8.  Apoptosis in coxsackievirus B3-caused diseases: interaction between the capsid protein VP2 and the proapoptotic protein siva.

Authors:  A Henke; H Launhardt; K Klement; A Stelzner; R Zell; T Munder
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

9.  Protection from lethal coxsackievirus-induced pancreatitis by expression of gamma interferon.

Authors:  M S Horwitz; T Krahl; C Fine; J Lee; N Sarvetnick
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

10.  Interleukin (IL)-10, IL-12, and interferon-gamma production in primary and memory immune responses to varicella-zoster virus.

Authors:  D E Jenkins; R L Redman; E M Lam; C Liu; I Lin; A M Arvin
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

View more
  17 in total

1.  Analysis of translational initiation in coxsackievirus B3 suggests an alternative explanation for the high frequency of R+4 in the eukaryotic consensus motif.

Authors:  Stephanie Harkins; Christopher T Cornell; J Lindsay Whitton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin-10 disorders.

Authors:  Gudrun Szalay; Martina Sauter; Joachim Hald; Andreas Weinzierl; Reinhard Kandolf; Karin Klingel
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

3.  beta2-microglobulin-associated regulation of interferon-gamma and virus-specific immunoglobulin G confer resistance against the development of chronic coxsackievirus myocarditis.

Authors:  Karin Klingel; Jens-Jörg Schnorr; Martina Sauter; Gudrun Szalay; Reinhard Kandolf
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

4.  Dynamics of molecular responses to coxsackievirus B4 infection differentiate between resolution and progression of acute pancreatitis.

Authors:  Rui Gu; Anae Shampang; Andrew Reilly; Dusti Fisher; William Glass; Arlene I Ramsingh
Journal:  Virology       Date:  2012-03-11       Impact factor: 3.616

5.  Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro.

Authors:  Ralph Feuer; Ignacio Mena; Robb Pagarigan; Mark K Slifka; J Lindsay Whitton
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression.

Authors:  Fayna Diaz-San Segundo; Mauro P Moraes; Teresa de Los Santos; Camila C A Dias; Marvin J Grubman
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

7.  Biological significance of a human enterovirus B-specific RNA element in the 3' nontranslated region.

Authors:  Ingrid Merkle; Mark J M van Ooij; Frank J M van Kuppeveld; Dirk H R F Glaudemans; Jochem M D Galama; Andreas Henke; Roland Zell; Willem J G Melchers
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons.

Authors:  Mauro Pires Moraes; Teresa de Los Santos; Marla Koster; Traci Turecek; He Wang; Vladimir G Andreyev; Marvin J Grubman
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

9.  Interferons in enteroviral heart disease: modulation of cytokine expression and antiviral activity.

Authors:  Albert Heim; Sabine Weiss
Journal:  Med Microbiol Immunol       Date:  2003-09-12       Impact factor: 3.402

10.  IL-10 is pathogenic during the development of coxsackievirus B4-induced chronic pancreatitis.

Authors:  Rui Gu; Anae Shampang; Andrew Reilly; Dusti Fisher; William Glass; Arlene I Ramsingh
Journal:  Virology       Date:  2009-10-01       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.